Degradation of plasmin-resistant fibrinogen-fibrin breakdown products in rheumatoid synovial fluid by Brinastrase.
D000818:Animals; D000941:Antigens; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000378:metabolism*; D005337:Fibrin / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism*; D005341:Fibrinolysin / Q000378:metabolism; D006801:Humans; D007106:Immune Sera; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D007270:Injections, Intra-Articular; D008259:Macroglobulins / Q000378:metabolism; D008970:Molecular Weight; D010452:Peptide Biosynthesis; D010447:Peptide Hydrolases / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits / Q000276:immunology; D012204:Rh-Hr Blood-Group System; D013582:Synovial Fluid / Q000187:drug effects* / Q000276:immunology; D000515:alpha 1-Antitrypsin / Q000378:metabolism
D000941:Antigens; D007106:Immune Sera; D008259:Macroglobulins; D012204:Rh-Hr Blood-Group System; D000515:alpha 1-Antitrypsin; D005337:Fibrin; D005340:Fibrinogen; D010447:Peptide Hydrolases; D005341:Fibrinolysin